Journal
EXPERT REVIEW OF ANTICANCER THERAPY
Volume 11, Issue 8, Pages 1277-1282Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1586/ERA.11.112
Keywords
anastrozole; aromatase inhibitors; chemoprevention trials; cognitive dysfunction; diffusion tensor radiological imaging; estrogen receptor; exemestane; letrozole; neurological functional imaging; neuropsychological testing; postmenopausal; tamoxifen
Categories
Ask authors/readers for more resources
As mortality in breast cancer patients has improved, morbidity of treatment has become increasingly important. Cognitive dysfunction has been considered as a morbid condition that may possibly result from aromatase inhibitor therapy, the standard treatment in postmenopausal, estrogen/progesterone receptor-positive breast cancer patients. Chemotherapy has been associated with cognitive dysfunction through neuropsychological testing and neurological functional imaging, but the relationship between estrogen and cognition remains largely unexplained. In focusing on aromatase inhibitor therapy, most of the studies yielding mixed results have been limited by confounders and small numbers of populations studied. This article briefly summarizes the major studies evaluating aromatase inhibitor therapy and cognitive dysfunction while considering new directions in future study design.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available